ClinicalTrials.gg
RecruitingNCT07737340MASHIV-TRUpdated Jul 30, 2026

Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)

An observational study in HIV Infections, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH) and Fatty Liver, sponsored by Yaşar Bayındır, MD. Recruiting at 11 sites in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Yaşar Bayındır, MD · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
411
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to identify the risk factors that lead to the development of metabolic liver disease in people who have been newly diagnosed with HIV. The research will take place across 9 centers in Türkiye and plans to include 250 newly diagnosed individuals with HIV, alongside 161 healthy individuals without HIV as a control group.

Participants will have their liver health checked when they first join the study (baseline) and then once a year for up to 5 years (at 12, 24, 36, 48, and 60 months). The main goal of these visits is to monitor their metabolic health and understand who is at risk of developing a fatty liver condition known as MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease).

During each visit, the research team will collect information about the participants' general health, including their height, weight, medical and family history, lifestyle habits, and sleep patterns. They will also record any medications being taken, including HIV treatments. To thoroughly check liver health, researchers will use routine blood tests (measuring things like cholesterol, blood sugar, and kidney function) and painless, non-invasive imaging tests, such as ultrasounds and FibroScans, to measure liver fat and stiffness.

Read the detailed description

Background and Rationale:

The prospective determination of risk factors associated with the development of metabolic liver disease is of critical clinical importance, particularly in newly diagnosed People Living with HIV (PLWH). This multi-center, prospective, observational cohort study aims to identify and monitor the risk factors contributing to the development of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in newly diagnosed PLWH, compared to an HIV-negative healthy control group.

Study Design and Population:

The study will be conducted across 9 centers in Turkey (Adana, Ankara, Antalya, Diyarbakır, Gaziantep, İstanbul, İzmir, Kocaeli, and Şanlıurfa). The targeted enrollment is a total of 411 participants, consisting of 250 newly diagnosed HIV-positive individuals and 161 HIV-negative healthy controls.

Methodology and Follow-up:

Participants in both the patient and control groups will undergo comprehensive clinical, laboratory, and radiological evaluations at the time of diagnosis (baseline) and subsequently every 12 months for a total follow-up period of 5 years (60 months). By longitudinally tracking metabolic, anthropometric, and hepatic parameters, the study will map the incidence of MASLD and stratify the metabolic risk factors over time.

Clinical Assessments (Conducted at Baseline, 12, 24, 36, 48, and 60 months):

To ensure standardization across all follow-up visits, the following parameters will be uniformly evaluated at every study time point:

Demographic and Clinical Characteristics: BMI (Height and Weight), comprehensive medical history, family history, presence of comorbidities, current medications, lifestyle habits, alcohol and substance use, and sleep patterns.

HIV-Specific Parameters: Details of the initiated Antiretroviral Therapy (ART) regimen.

Laboratory Parameters: Fasting glucose, HOMA-IR score, Lipid profile (Total Cholesterol, Triglycerides, LDL, HDL, LDL/HDL ratio, VLDL), Renal function tests (GFR, creatinine, urea, proteinuria), and systemic/hepatic markers (CRP, AFP, INR, FIB-4 index).

Radiological and Non-Invasive Hepatic Evaluations: Hepatobiliary ultrasonography (USG) and FibroScan measurements (recording both Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) values).

02

Conditions studied

  • HIV Infections
  • Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
  • Fatty Liver

Keywords

  • HIV
  • Newly Diagnosed HIV Infection
  • Antiretroviral Therapy (ART)
  • Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Metabolic Syndrome
03

In context

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's planned enrollment of 411 is above the median of 200 across 781 observational studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

Yaşar Bayındır, MD is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

he study population consists of 411 adult participants (≥ 18 years of age) who are citizens of the Republic of Türkiye, enrolled across 9 different clinical centers nationwide (Adana, Ankara, Antalya, Diyarbakır, Gaziantep, İstanbul, İzmir, Kocaeli, and Şanlıurfa). The population is divided into two distinct cohorts: a patient group comprising 250 newly diagnosed individuals living with HIV who are initiating Antiretroviral Therapy (ART), and a comparative control group comprising 161 healthy, HIV-negative individuals.

Eligibility criteria

Inclusion Criteria (For the Patient Group / Newly Diagnosed +):

  • Citizens of the Republic of Türkiye
  • Adults (≥ 18 years of age)
  • Confirmed Anti-HIV positive (Newly diagnosed)
  • Patients who are initiating Antiretroviral Therapy (ART)

Inclusion Criteria (For the Healthy Control Group / HIV-):

  • Citizens of the Republic of Türkiye
  • Adults (≥ 18 years of age)
  • Confirmed Anti-HIV negative

Exclusion Criteria:

  • There are no specified exclusion criteria for this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
411 participants (estimated)
Target follow-up
60 Months
Patient registry
Yes

Groups and cohorts

  • Newly Diagnosed HIV Patients

    250 individuals newly diagnosed with HIV who are initiating Antiretroviral Therapy (ART). This group will be prospectively monitored for the development of metabolic liver disease and MASLD risk factors over 60 months.

    Diagnostic Test: FibroScan (Transient Elastography) · Diagnostic Test: Hepatobiliary Ultrasonography (USG) · Other: Clinical and Laboratory Monitoring

  • Healthy Controls

    161 healthy individuals without an HIV diagnosis. This group will serve as the comparative control group and will undergo the same prospective metabolic and hepatic evaluations over 60 months.

    Diagnostic Test: FibroScan (Transient Elastography) · Diagnostic Test: Hepatobiliary Ultrasonography (USG) · Other: Clinical and Laboratory Monitoring

Interventions

  • Diagnostic testFibroScan (Transient Elastography)

    Non-invasive measurement of liver stiffness (LSM) and controlled attenuation parameter (CAP) to evaluate liver fibrosis and steatosis. Measurements are taken at baseline and annually up to 60 months.

  • Diagnostic testHepatobiliary Ultrasonography (USG)

    Routine ultrasound imaging of the liver and biliary tract to evaluate signs of metabolic liver disease and fatty liver. Assessed at baseline and annually up to 60 months.

  • OtherClinical and Laboratory Monitoring

    Annual monitoring including anthropometric measurements (BMI), lipid profile, fasting glucose, HOMA-IR score, renal and liver function tests, and calculation of the FIB-4 index. For the patient group, details of the initiated Antiretroviral Therapy (ART) will also be recorded.

06

What researchers measure

Primary outcomes

  1. Change in Hepatic Steatosis (CAP)

    The development and progression of hepatic steatosis will be quantitatively assessed using FibroScan to record the Controlled Attenuation Parameter (CAP, measured in dB/m). Changes in CAP values will be compared between newly diagnosed HIV patients and healthy controls.

    Time frame: Baseline, 12, 24, 36, 48, and 60 months

  2. Change in Liver Fibrosis (LSM)

    The development and progression of liver fibrosis will be quantitatively assessed using FibroScan to record the Liver Stiffness Measurement (LSM, measured in kPa). Changes in LSM values will be compared between newly diagnosed HIV patients and healthy controls.

    Time frame: Baseline, 12, 24, 36, 48, and 60 months

07

Study locations

11 of 11 sites recruiting
  • Guven Hospital
    Ankara, Ankara 06850, Turkey (Türkiye)
    Recruiting
  • Adana Acıbadem Hospital
    Adana, Turkey (Türkiye)
    Recruiting
    • Behice Kurtaran, MD, Prof. · Contactbehicekurtaran@gmail.com · +905327393613
    • Behice Kurtaran, MD, Prof. · Principal investigator
  • Cukurova University, Faculty of Medicine
    Adana, Turkey (Türkiye)
    Recruiting
    • Yesim Tasova, MD, Prof. · Contactytasova@gmail.com · +905353088511
    • Yesim Tasova, MD, Prof. · Principal investigator
  • Hacettepe University, Faculty of Medicine
    Ankara, Turkey (Türkiye)
    Recruiting
    • Ahmet Cagkan Inkaya, MD, Prof. · Contactinkaya@hacettepe.edu.tr · +905326828702
    • Ahmet Cagkan Inkaya, MD, Prof. · Principal investigator
    • Nursel Calik Basaran, MD, Prof. · Sub investigator
    • Meliha Cagla Sonmezer, MD, Assoc. Prof. · Sub investigator
  • Akdeniz University, Faculty of Medicine
    Antalya, Turkey (Türkiye)
    Recruiting
    • Dilara Inan, MD, Prof. · Contactinan@akdeniz.edu.tr · +905323706725
    • Dilara Inan, MD, Prof. · Principal investigator
  • Dicle University, Faculty of Medicine
    Diyarbakır, TR21280, Turkey (Türkiye)
    Recruiting
    • Mustafa Kemal Celen, MD, Prof. · Contactmkcelen@hotmail.com · +905336207022
    • Mustafa Kemal Celen, MD, Prof. · Principal investigator
    • Cigdem Mermutluoglu, MD, Assoc. Prof. · Sub investigator
  • Gaziantep University, Faculty of Medicine
    Gaziantep, Turkey (Türkiye)
    Recruiting
    • İlkay Karaoglan, MD, Prof. · Contactilkayn.can@gmail.com · +905359266763
    • Ilkay Karaoglan, MD, Prof. · Principal investigator
    • Ayse Ozlem Mete, MD, Assoc. Prof. · Sub investigator
  • Health Sciences University Hamidiye Faculty of Medicine
    Istanbul, Turkey (Türkiye)
    Recruiting
    • Funda Simsek, MD, Prof. · Contactfundasimsek67@gmail.com · +905325620953
    • Funda Simsek, MD, Prof. · Principal investigator
  • Ege University, Faculty of Medicine
    Izmir, Turkey (Türkiye)
    Recruiting
    • Husnu Pullukcu, MD, Prof. · Contacthusnup@yahoo.com · +905334231918
    • Husnu Pullukcu, MD, Prof. · Principal investigator
  • Kocaeli University, Faculty of Medicine
    Kocaeli, Turkey (Türkiye)
    Recruiting
    • Sila Akhan, MD, Prof. · Contactsila.akhan@kocaeli.edu.tr · +905322666535
    • Sila Akhan, MD, Prof. · Principal investigator
  • Harran University, Faculty of Medicine
    Sanliurfa, Turkey (Türkiye)
    Recruiting
    • Tuba Damar Cakirca, MD, Assoc. Prof. · Contactdr.tubadamar@gmail.com · +905444495379
    • Tuba Damar Cakirca, MD, Assoc. Prof. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for May 2027, 35 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 35 months is close to that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartActual
Jun 1, 2024
Primary completionEst.
May 2027
CompletionEst.
May 31, 2029
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07737340
Lead sponsor
Yaşar Bayındır, MD
Collaborators
Ilko Ilac San. ve Tic. A.S.
Responsible party
Yaşar Bayındır, MD (Chief Physician, Prof. Dr., M.D., Guven Health Group) — Sponsor-investigator
First posted
Jul 30, 2026
Start date
Jun 1, 2024
Primary completion
May 2027 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jul 30, 2026

Study contacts

Yaşar Bayındır, MD, Prof.
Contact
yasar.bayindir@guven.com.tr
+905323659909

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion